{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:33:55Z","timestamp":1791182035481,"version":"4.1.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: Molecular characterization of Philadelphia chromosome\u2013negative (Ph\u2212) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib in vitro, significantly inhibiting wild-type KIT and platelet-derived growth factor receptor \u03b2 TKs, and is active against cells carrying the mutant KIT-D816V gene.<\/jats:p>\n               <jats:p>Experimental Design: In this phase 2, open-label study, the efficacy of dasatinib (140 mg\/d) was investigated in 67 patients with various Ph\u2212 myeloid disorders, including SM (n = 33; 28 KIT-D816V positive).<\/jats:p>\n               <jats:p>Results: The overall response rate to dasatinib in patients with SM was 33%. Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. Both patients were negative for KIT-D816V mutation, had low tryptase levels, abnormal WBC counts, and anemia, and had failed prior therapy with erythropoietin. Additional nine SM patients had symptomatic response, lasting 3 to 18+ months. Complete responses were achieved in two other patients (acute myeloid leukemia and hypereosinophilic syndrome). No responses were observed among patients with myelodysplastic syndromes and primary myelofibrosis. The majority of adverse events were grade 1\/2.<\/jats:p>\n               <jats:p>Conclusion: These data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-08-0366","type":"journal-article","created":{"date-parts":[[2008,6,16]],"date-time":"2008-06-16T18:33:36Z","timestamp":1213641216000},"page":"3906-3915","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["Phase II Study of Dasatinib in Philadelphia Chromosome\u2013Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis"],"prefix":"10.1158","volume":"14","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[{"name":"1Leukemia Department, M. D. Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"1Leukemia Department, M. D. Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"1Leukemia Department, M. D. Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"1Leukemia Department, M. D. Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[{"name":"3University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"1Leukemia Department, M. D. Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghi","family":"Manshouri","sequence":"additional","affiliation":[{"name":"1Leukemia Department, M. D. Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[{"name":"1Leukemia Department, M. D. Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1Leukemia Department, M. D. Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,6,16]]},"reference":[{"key":"2022061021442888300_B1","doi-asserted-by":"crossref","unstructured":"Deininger M, Buchdunger E, Drucker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood\u20082005;105:2640\u201353.","DOI":"10.1182\/blood-2004-08-3097"},{"key":"2022061021442888300_B2","doi-asserted-by":"crossref","unstructured":"Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med\u20082006;355:2452\u201366.","DOI":"10.1056\/NEJMra063728"},{"key":"2022061021442888300_B3","doi-asserted-by":"crossref","unstructured":"Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res\u20082001;25:603\u201325.","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"2022061021442888300_B4","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol\u20082003;122:695\u2013717.","DOI":"10.1046\/j.1365-2141.2003.04575.x"},{"key":"2022061021442888300_B5","doi-asserted-by":"crossref","unstructured":"Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J\u20081987;6:3341\u201351.","DOI":"10.1002\/j.1460-2075.1987.tb02655.x"},{"key":"2022061021442888300_B6","doi-asserted-by":"crossref","unstructured":"Valent P, Spanblochl E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor\/kit-ligand in long-term culture. Blood\u20081992;80:2237\u201345.","DOI":"10.1182\/blood.V80.9.2237.bloodjournal8092237"},{"key":"2022061021442888300_B7","doi-asserted-by":"crossref","unstructured":"Wang B, Tsukada J, Higashi T, et al. Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125. Genes Cells\u20082006;11:983\u201392.","DOI":"10.1111\/j.1365-2443.2006.01005.x"},{"key":"2022061021442888300_B8","doi-asserted-by":"crossref","unstructured":"Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest\u20081993;92:1736\u201344.","DOI":"10.1172\/JCI116761"},{"key":"2022061021442888300_B9","doi-asserted-by":"crossref","unstructured":"Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A\u20081995;92:10560\u20134.","DOI":"10.1073\/pnas.92.23.10560"},{"key":"2022061021442888300_B10","doi-asserted-by":"crossref","unstructured":"Fritsche-Polanz R, Jordan JH, Feix A, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol\u20082001;113:357\u201364.","DOI":"10.1046\/j.1365-2141.2001.02783.x"},{"key":"2022061021442888300_B11","doi-asserted-by":"crossref","unstructured":"Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet\u20081996;12:312\u20134.","DOI":"10.1038\/ng0396-312"},{"key":"2022061021442888300_B12","doi-asserted-by":"crossref","unstructured":"Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol\u20082006;24:3904\u201311.","DOI":"10.1200\/JCO.2006.06.9500"},{"key":"2022061021442888300_B13","doi-asserted-by":"crossref","unstructured":"Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood\u20082003;102:3093\u20136.","DOI":"10.1182\/blood-2003-05-1627"},{"key":"2022061021442888300_B14","doi-asserted-by":"crossref","unstructured":"Swolin B, Rodjer S, Roupe G. Cytogenetic studies in patients with mastocytosis. Cancer Genet Cytogenet\u20082000;120:131\u20135.","DOI":"10.1016\/S0165-4608(99)00256-3"},{"key":"2022061021442888300_B15","doi-asserted-by":"crossref","unstructured":"Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood\u20082004;104:3038\u201345.","DOI":"10.1182\/blood-2004-03-0787"},{"key":"2022061021442888300_B16","doi-asserted-by":"crossref","unstructured":"Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFR\u03b1 fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood\u20082004;103:2879\u201391.","DOI":"10.1182\/blood-2003-06-1824"},{"key":"2022061021442888300_B17","doi-asserted-by":"crossref","unstructured":"Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A\u20082003;100:7830\u20135.","DOI":"10.1073\/pnas.0932698100"},{"key":"2022061021442888300_B18","doi-asserted-by":"crossref","unstructured":"Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res\u20082001;80:1\u201338.","DOI":"10.1016\/S0065-230X(01)80010-5"},{"key":"2022061021442888300_B19","doi-asserted-by":"crossref","unstructured":"Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol\u20082003;31:686\u201392.","DOI":"10.1016\/S0301-472X(03)00112-7"},{"key":"2022061021442888300_B20","unstructured":"Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther\u20082000;295:139\u201345."},{"key":"2022061021442888300_B21","doi-asserted-by":"crossref","unstructured":"Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene\u20082003;22:660\u20134.","DOI":"10.1038\/sj.onc.1206120"},{"key":"2022061021442888300_B22","unstructured":"Frost M, Ferrao PT, Hughes TP, et al. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-Kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther\u20082002;1:1115\u201324."},{"key":"2022061021442888300_B23","doi-asserted-by":"crossref","unstructured":"Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory type mutations. Blood\u20082002;99:1741\u20134.","DOI":"10.1182\/blood.V99.5.1741"},{"key":"2022061021442888300_B24","doi-asserted-by":"crossref","unstructured":"Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet\u20082003;362:535\u20136.","DOI":"10.1016\/S0140-6736(03)14115-3"},{"key":"2022061021442888300_B25","doi-asserted-by":"crossref","unstructured":"Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer\u20082006;107:345\u201351.","DOI":"10.1002\/cncr.21996"},{"key":"2022061021442888300_B26","doi-asserted-by":"crossref","unstructured":"Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood\u20082003;101:4714\u20136.","DOI":"10.1182\/blood-2003-01-0081"},{"key":"2022061021442888300_B27","doi-asserted-by":"crossref","unstructured":"Salem Z, Zalloua PA, Chehal A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J\u20082003;4:410\u20132.","DOI":"10.1038\/sj.thj.6200294"},{"key":"2022061021442888300_B28","doi-asserted-by":"crossref","unstructured":"Tashiro H, Shirasaki R, Noguchi M, et al. Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate. Int J Hematol\u20082006;83:433\u20138.","DOI":"10.1532\/IJH97.05180"},{"key":"2022061021442888300_B29","doi-asserted-by":"crossref","unstructured":"Hasselbalch HC, Bjerrum OW, Jensen BA, et al. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am J Hematol\u20082003;74:238\u201342.","DOI":"10.1002\/ajh.10431"},{"key":"2022061021442888300_B30","doi-asserted-by":"crossref","unstructured":"Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood\u20082002;99:3854\u20136.","DOI":"10.1182\/blood-2001-12-0154"},{"key":"2022061021442888300_B31","doi-asserted-by":"crossref","unstructured":"David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood\u20082007;109:61\u20134.","DOI":"10.1182\/blood-2006-05-024828"},{"key":"2022061021442888300_B32","doi-asserted-by":"crossref","unstructured":"Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood\u20082007;109:4635\u201340.","DOI":"10.1182\/blood-2006-10-050054"},{"key":"2022061021442888300_B33","doi-asserted-by":"crossref","unstructured":"Musto P, Falcone A, Sanpaolo G, et al. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leuk Res\u20082004;28:421\u20132.","DOI":"10.1016\/j.leukres.2003.09.001"},{"key":"2022061021442888300_B34","doi-asserted-by":"crossref","unstructured":"Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer\u20082006;107:1429\u201339.","DOI":"10.1002\/cncr.22187"},{"key":"2022061021442888300_B35","doi-asserted-by":"crossref","unstructured":"Kalac M, Quintas-Cardama A, Vrhovac R, et al. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer\u20082007;110:955\u201364.","DOI":"10.1002\/cncr.22920"},{"key":"2022061021442888300_B36","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Quintas-Cardama A, Kantarjian H, et al. Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs\u20082006;15:1555\u201363.","DOI":"10.1517\/13543784.15.12.1555"},{"key":"2022061021442888300_B37","doi-asserted-by":"crossref","unstructured":"Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood\u20082007;109:3207\u201313.","DOI":"10.1182\/blood-2006-09-046888"},{"key":"2022061021442888300_B38","doi-asserted-by":"crossref","unstructured":"Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood\u20082007;109:4143\u201350.","DOI":"10.1182\/blood-2006-09-046839"},{"key":"2022061021442888300_B39","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood\u20082007;109:2303\u20139.","DOI":"10.1182\/blood-2006-09-047266"},{"key":"2022061021442888300_B40","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood\u20082007;109:5143\u201350.","DOI":"10.1182\/blood-2006-11-056028"},{"key":"2022061021442888300_B41","doi-asserted-by":"crossref","unstructured":"O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res\u20082005;65:4500\u20135.","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"2022061021442888300_B42","doi-asserted-by":"crossref","unstructured":"Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem\u20082004;47:6658\u201361.","DOI":"10.1021\/jm049486a"},{"key":"2022061021442888300_B43","doi-asserted-by":"crossref","unstructured":"Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res\u20082006;66:473\u201381.","DOI":"10.1158\/0008-5472.CAN-05-2050"},{"key":"2022061021442888300_B44","doi-asserted-by":"crossref","unstructured":"Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood\u20082006;108:286\u201391.","DOI":"10.1182\/blood-2005-10-3969"},{"key":"2022061021442888300_B45","doi-asserted-by":"crossref","unstructured":"Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-\u03b1: results of a multicentre phase II trial on 20 patients. Br J Haematol\u20082002;119:1090\u20137.","DOI":"10.1046\/j.1365-2141.2002.03944.x"},{"key":"2022061021442888300_B46","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood\u20082003;102:4270\u20136.","DOI":"10.1182\/blood-2003-05-1699"},{"key":"2022061021442888300_B47","unstructured":"Lee FY, Lombardo L, Camuso A, et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo [abstract 675]. Proc Amer Assoc Cancer Res 2005;46."},{"key":"2022061021442888300_B48","doi-asserted-by":"crossref","unstructured":"Bergeron A, Re\u0301a D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med\u20082007;176:814\u20138.","DOI":"10.1164\/rccm.200705-715CR"},{"key":"2022061021442888300_B49","doi-asserted-by":"crossref","unstructured":"Quintas-Cardama A, Kantarjian HM, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol\u20082007;25:3908\u201314.","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"2022061021442888300_B50","doi-asserted-by":"crossref","unstructured":"Shah NP, Kim DW, Kantarjian HM, et al. Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034 [abstract 7004]. J Clin Oncol\u20082007;25:358S.","DOI":"10.1200\/jco.2007.25.18_suppl.7004"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/14\/12\/3906\/1974284\/3906.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/14\/12\/3906\/1974284\/3906.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T02:56:53Z","timestamp":1654916213000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/14\/12\/3906\/72773\/Phase-II-Study-of-Dasatinib-in-Philadelphia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,15]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2008,6,16]]},"published-print":{"date-parts":[[2008,6,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-0366","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,15]]}}}